European Journal of Surgical Oncology
Volume 34, Issue 12 , Pages 1309-1315 , December 2008

Outcome of R1 resection in patients undergoing pancreatico-duodenectomy for pancreatic cancer

  • G. Fusai

      Affiliations

    • University Department of Surgery and Liver Transplant Unit, Royal Free Hospital, Royal Free and University College Medical School, Pond Street, NW3 2QG London, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 207 7940500x31316; fax: +44 207 8302688.
    • ,
  • N. Warnaar

      Affiliations

    • University Department of Surgery and Liver Transplant Unit, Royal Free Hospital, Royal Free and University College Medical School, Pond Street, NW3 2QG London, United Kingdom
    • ,
  • C.A. Sabin

      Affiliations

    • Department of Primary Care & Population Sciences, Royal Free & University College Medical School, Rowland Hill Street, NW3 2PF London, United Kingdom
    • ,
  • S. Archibong

      Affiliations

    • University Department of Surgery and Liver Transplant Unit, Royal Free Hospital, Royal Free and University College Medical School, Pond Street, NW3 2QG London, United Kingdom
    • ,
  • B.R. Davidson

      Affiliations

    • University Department of Surgery and Liver Transplant Unit, Royal Free Hospital, Royal Free and University College Medical School, Pond Street, NW3 2QG London, United Kingdom

,Accepted 16 January 2008.

References 

  1. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg. 1995;82(1):111–115
  2. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg. 1999;189(1):1–7
  3. Kuhlmann KF, de Castro SM, Wesseling JG, et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer. 2004;40(4):549–558
  4. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237(1):74–85
  5. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567–579
  6. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91(5):586–594
  7. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10(9):1199–1210
  8. Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg. 1987;206(3):358–365
  9. Cameron JL, Pitt HA, Yeo C, Lillemoe KD, Kaufman HS, Coleman J. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg. 1993;217(5):430–435
  10. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996;223(3):273–279
  11. Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control. 2006;17(4):403–409
  12. Reinders ME, Allema JH, van Gulik TM, et al. Outcome of microscopically nonradical, subtotal pancreaticoduodenectomy (Whipple's resection) for treatment of pancreatic head tumors. World J Surg. 1995;19(3):410–414
  13. Lillemoe KD, Cameron JL, Yeo CJ, et al. Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer?. Ann Surg. 1996;223(6):718–725
  14. Kuhlmann K, de Castro S, van Heek T, et al. Microscopically incomplete resection offers acceptable palliation in pancreatic cancer. Surgery. 2006;139(2):188–196
  15. Ouchi K, Sugawara T, Ono H, et al. Palliative operation for cancer of the head of the pancreas: significance of pancreaticoduodenectomy and intraoperative radiation therapy for survival and quality of life. World J Surg. 1998;22(4):413–416
  16. Schniewind B, Bestmann B, Kurdow R, et al. Bypass surgery versus palliative pancreaticoduodenectomy in patients with advanced ductal adenocarcinoma of the pancreatic head, with an emphasis on quality of life analyses. Ann Surg Oncol. 2006;13(11):1403–1411
  17. Benassai G, Mastrorilli M, Quarto G, et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol. 2000;73(4):212–218
  18. Moon HJ, An JY, Heo JS, Choi SH, Joh JW, Kim YI. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas. 2006;32(1):37–43
  19. Khan AW, Agarwal AK, Davidson BR. Isolated Roux loop duct-to-mucosa pancreaticojejunostomy avoids pancreatic leaks in pancreaticoduodenectomy. Dig Surg. 2002;19(3):199–204
  20. Pederzoli P, Bassi C, Falconi M, Camboni MG. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Italian study group. Br J Surg. 1994;81(2):265–269
  21. Berge Henegouwen MI, van Gulik TM, DeWit LT, et al. Delayed gastric emptying after standard pancreaticoduodenectomy versus pylorus-preserving pancreaticoduodenectomy: an analysis of 200 consecutive patients. J Am Coll Surg. 1997;185(4):373–379
  22. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576–1585
  23. Luttges J, Vogel I, Menke M, Henne-Bruns D, Kremer B, Kloppel G. The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Virchows Arch. 1998;433(3):237–242
  24. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93(10):1232–1237
  25. Tsuchiya R, Noda T, Harada N, et al. Collective review of small carcinomas of the pancreas. Ann Surg. 1986;203(1):77–81
  26. Nagakawa T, Nagamori M, Futakami F, et al. Results of extensive surgery for pancreatic carcinoma. Cancer. 1996;77(4):640–645
  27. The Royal College of Pathologists. Standards and minimum datasets for reporting cancers. Minimum dataset for the histopathologic reporting of pancreatic, ampulla of Vater and bile duct carcinoma, February 2002.
  28. Fujino Y, Suzuki Y, Ajiki T, Tanioka Y, Ku Y, Kuroda Y. Predicting factors for survival of patients with unresectable pancreatic cancer: a management guideline. Hepatogastroenterology. 2003;50(49):250–253
  29. Wenger FA, Peter F, Zieren J, Steiert A, Jacobi CA, Muller JM. Prognosis factors in carcinoma of the head of the pancreas. Dig Surg. 2000;17(1):29–35
  30. Ahmad NA, Lewis JD, Ginsberg GG, et al. Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol. 2001;96(9):2609–2615
  31. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165(1):68–72
  32. Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246(1):52–60
  33. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8(8):935–949
  34. Bassi C, Stocken DD, Olah A, et al. Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial. Dig Surg. 2005;22(5):353–363
  35. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234(6):758–768
  36. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. J Am Med Assoc. 2007;297(3):267–277

PII: S0748-7983(08)00033-4

doi: 10.1016/j.ejso.2008.01.017

European Journal of Surgical Oncology
Volume 34, Issue 12 , Pages 1309-1315 , December 2008

Article Tools

* Image Usage & Resolution